Drug Trial Radar · NCT04366115
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Dec 1, 2031
Study completion Mar 1, 2032
Sponsor
- Lead sponsor
- AVM Biotechnology IncIndustry
- Sponsor type
- Industry
- First posted
- Apr 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a single intravenous (IV) infusion to patients with moderate or severe immediately life-threatening Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 or influenza (A or B). The study is designed to evaluate the safety, tolerability, and pharmacokinetics of single dose of AVM0703 in these ARDS patients.
Conditions
- ARDS
- Covid19
- Influenza, Human
Interventions
AVM0703Drug
Single IV infusion at 10 mg/mL in normal saline over 1 hour to patients.
PlaceboDrug
Single IV infusion in normal saline over 1 hour to patients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting ToxicitiesTime frame: 0-12 months
- 28 day all-cause mortality will be a primary end point for Phase 1 and 2Time frame: 0-12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.